{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 979083, "exercisedValue": 0, "unexercisedValue": 486940}, {"maxAge": 1, "name": "Dr. Steven B. Kanner Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 669310, "exercisedValue": 0, "unexercisedValue": 447452}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 669310, "exercisedValue": 0, "unexercisedValue": 402144}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 42, "title": "Chief Financial Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 54, "title": "Chief Technology Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 48, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9131, "open": 0.9377, "dayLow": 0.8363, "dayHigh": 0.9377, "regularMarketPreviousClose": 0.9131, "regularMarketOpen": 0.9377, "regularMarketDayLow": 0.8363, "regularMarketDayHigh": 0.9377, "payoutRatio": 0.0, "beta": 2.338, "forwardPE": -0.4226633, "volume": 801193, "regularMarketVolume": 801193, "averageVolume": 1234580, "averageVolume10days": 1016350, "averageDailyVolume10Day": 1016350, "bid": 0.8085, "ask": 0.8752, "bidSize": 8, "askSize": 5, "marketCap": 78226168, "fiftyTwoWeekLow": 0.836, "fiftyTwoWeekHigh": 4.915, "priceToSalesTrailing12Months": 7.8273134, "fiftyDayAverage": 1.2111, "twoHundredDayAverage": 1.788225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -104823832, "profitMargins": 0.0, "floatShares": 83939443, "sharesOutstanding": 93004600, "sharesShort": 8824727, "sharesShortPriorMonth": 8907755, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0949, "heldPercentInsiders": 0.100839995, "heldPercentInstitutions": 0.61638, "shortRatio": 8.49, "shortPercentOfFloat": 0.099300005, "impliedSharesOutstanding": 93004600, "bookValue": 2.738, "priceToBook": 0.30719504, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -149104992, "trailingEps": -1.65, "forwardEps": -1.99, "enterpriseToRevenue": -10.489, "enterpriseToEbitda": 0.663, "52WeekChange": -0.82029915, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.8411, "targetHighPrice": 34.0, "targetLowPrice": 3.0, "targetMeanPrice": 12.0, "targetMedianPrice": 10.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 209536992, "totalCashPerShare": 2.253, "ebitda": -158188992, "totalDebt": 26487000, "quickRatio": 6.942, "currentRatio": 7.157, "totalRevenue": 9994000, "debtToEquity": 10.471, "revenuePerShare": 0.111, "returnOnAssets": -0.27181998, "returnOnEquity": -0.47994, "grossProfits": -119559000, "freeCashflow": -84897504, "operatingCashflow": -138200000, "revenueGrowth": -0.416, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -18.42802, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -7.8852286, "regularMarketPrice": 0.8411, "marketState": "PRE", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "corporateActions": [], "regularMarketTime": 1743537600, "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": -0.07200003, "regularMarketDayRange": "0.8363 - 0.9377", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1234580, "fiftyTwoWeekLowChange": 0.005099952, "fiftyTwoWeekLowChangePercent": 0.0061004213, "fiftyTwoWeekRange": "0.836 - 4.915", "fiftyTwoWeekHighChange": -4.0739, "fiftyTwoWeekHighChangePercent": -0.82887083, "fiftyTwoWeekChangePercent": -82.029915, "epsTrailingTwelveMonths": -1.65, "epsForward": -1.99, "epsCurrentYear": -1.74, "priceEpsCurrentYear": -0.48339078, "fiftyDayAverageChange": -0.37, "fiftyDayAverageChangePercent": -0.3055074, "twoHundredDayAverageChange": -0.9471251, "twoHundredDayAverageChangePercent": -0.5296453, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "displayName": "Caribou Biosciences", "trailingPegRatio": null}